Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

Authors:

Abstract
No abstract available
Funding Information
  • Merck
  • Merck KGaA
  • Pfizer

This publication has 21 references indexed in Scilit: